RenovoRx sees 2nd interim analysis on Phase III TIGeR-PaC by 2024-end

RenovoRx provided a letter to shareholders from Chief Executive Officer, Shaun Bagai. ” … We are proud to have achieved several key milestones described below, including, importantly, an initial positive interim analysis on our pivotal Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer or LAPC. Among our significant milestones achieved, our recent completion of a $6.1M private placement has extended our cash runway, allowing us to drive towards our key goal of a second interim analysis for our TIGeR-PaC study, which is expected by late 2024. ..As a result of the positive progress that we have made in advancing TAMP with our TIGeR-PaC study, we made important additions to our management team, Board of Directors, and Scientific Advisory Board, bolstering our strong leadership. These additions enhance our already deep expertise resident at RenovoRx. …As we make strong progress on our clinical pathway, it is critically important that we continue to invest in our intellectual property. In December 2023, we filed an additional international patent application under the Patent Cooperation Treaty for our novel TAMP therapy platform. RenovoRx already holds a strong intellectual property portfolio with nine patents issued and nine pending patents for our proprietary TAMP platform and delivery system in the US, EU, and Asia.”